Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8017575-B2
Publication Date
2011-09-13
Expiration Date
Abstract
The present invention provides the use of somatostatin antagonists for treating and preventing HISS-dependent insulin resistance and hemorrhage induced insulin resistance. The present further provides pharmaceutical compositions comprising a somatostatin antagonist and a pharmaceutically acceptable liver targeting compound.
Core Innovation
The invention relates to treating and preventing HISS-dependent insulin resistance (HDIR) by administering a somatostatin antagonist to a patient in need thereof. The document characterizes HDIR as HISS-dependent insulin resistance and provides a relationship to somatostatin receptor signaling, including type 2 somatostatin receptor antagonism.
The invention also addresses hemorrhage-induced insulin resistance by treating hemorrhage induced insulin resistance that is HISS-dependent insulin resistance. The disclosed approach uses administering a therapeutically effective amount of a somatostatin antagonist to a patient, including cyclosomatostatin as a notably described antagonist.
The document further discloses pharmaceutical compositions that combine a somatostatin receptor antagonist with liver-targeting compounds, including albumin, bile salt, and liposome. Experimental evidence described in the document uses Rapid Insulin Sensitivity Test (RIST) measurements, including disclosures that hemorrhage causes full HDIR, that somatostatin infusion induces HDIR, and that cyclosomatostatin prevents somatostatin- and hemorrhage-induced HDIR.
Claims Coverage
The document includes two independent method claims grounded in administering a therapeutically effective amount of a somatostatin antagonist to treat HISS-dependent insulin resistance or hemorrhage-induced insulin resistance that is HISS-dependent insulin resistance.
Treating HISS-dependent insulin resistance by administering a somatostatin antagonist
A method of treating HISS-dependent insulin resistance comprising administering a therapeutically effective amount of a somatostatin antagonist to a patient in need thereof.
Treating hemorrhage induced insulin resistance by administering a somatostatin antagonist where the insulin resistance is HISS-dependent
A method of treating hemorrhage induced insulin resistance comprising administering a therapeutically effective amount of a somatostatin antagonist to a patient in need thereof, wherein the hemorrhage induced insulin resistance is HISS-dependent insulin resistance.
Across the independent claims, the central inventive concept is that HISS-dependent insulin resistance, including hemorrhage-induced HISS-dependent insulin resistance, is treated by administering a therapeutically effective amount of a somatostatin antagonist to a patient in need thereof.
Stated Advantages
Cyclosomatostatin prevents somatostatin- and hemorrhage-induced HDIR.
Alpha- and beta-adrenergic blockade do not prevent HDIR after hemorrhage.
Documented Applications
Treating and preventing HISS-dependent insulin resistance (HDIR).
Treating hemorrhage-induced insulin resistance that is HISS-dependent insulin resistance.
Interested in licensing this patent?